Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00576-8 Epub ahead of print
The data gathered in this post-marketing surveillance study aligned with the previously established safety profile of tofacitinib, and reports were found to have consistent safety profiles in the treatment of both patient with PsA and RA. However, the results of this study should be interpreted considering the limitations of post-marketing surveillance studies.
Currently, post-marketing surveillance safety data from adverse event reports on the use of tofacitinib to treat patients with RA have been published. However, the same data have not been published for patients with PsA. The data from this study provides a valuable insight into the expected real-world safety outcomes of patients with PsA treated with tofacitinib.